English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background:   BRCA1  and  BRCA2  have been identified as high-penetrance breast cancer predisposition genes, but they only account for a small fraction of the inherited component of breast cancer. To explain the remaining cases, a polygenic model with a large number of low- to moderate-penetrance genes have been proposed; one of these, is the  CHEK2  gene (Checkpoint Kinase 2). The objective of this study was to determine the role of the  CHEK2  gene, specifically the c.1100delC mutation in familial breast cancer susceptibility in Colombian patients.    Methods:  We screened 131 high-risk breast and/or ovarian cancer patients (negative for mutations in BRCA1 and BRCA2) and 131 controls for the germline mutation  CHEK2  c.1100delC by allele-specific PCR.    Results:  None of the cases or controls showed the CHEK2 c.1100delC mutation, neither as a homozygote nor as a heterozygote.    Conclusions:  Our results suggest that the CHEK2 c.1100delC mutation is not a risk factor for genetic susceptibility to familial breast or ovarian cancer in the Colombian population.  The absence of the  CHEK2  c . 1100delC mutation in our population show the importance of considering ethnic background before offering a genetic test.

Absence of the CHEK2 c.1100delC mutation in familial breast and ovarian cancer in Colombia: a case-control study